Three-Year Follow-Up Analysis of Kite's Yescarta® CAR T-cell Therapy - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months Pharmaceutical Investing
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Pharmaceutical Investing
Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx for the Treatment of Recurrent Pericarditis Pharmaceutical Investing
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio Pharmaceutical Investing
AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting Evaluating Epcoritamab Across B-Cell Lymphomas Pharmaceutical Investing
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite's Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis Pharmaceutical Investing
AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients Pharmaceutical Investing
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial Pharmaceutical Investing
AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting Adds to Robust IMBRUVICA® Science Pharmaceutical Investing
